Thermo Fisher Scientific (NYSE:TMO) Upgraded by Sanford C. Bernstein to Hold Rating

Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific (NYSE:TMO) to a hold rating in a research note released on Thursday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Piper Sandler began coverage on Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Finally, Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $605.09.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $513.54 on Thursday. The business’s 50-day moving average price is $474.08 and its 200 day moving average price is $520.19. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific has a twelve month low of $401.45 and a twelve month high of $643.99. The company has a market capitalization of $190.84 billion, a PE ratio of 28.23, a price-to-earnings-growth ratio of 2.24 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts predict that Thermo Fisher Scientific will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TMO. Legacy Wealth Managment LLC ID grew its stake in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. High Note Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $28,000. Finally, Beacon Financial Strategies CORP acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $29,000. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.